Company Overview of Bayer Pharma AG
Bayer Pharma AG is engaged in the research and development of drugs and novel therapeutics for cardiovascular and blood diseases, oncological diseases, ophthalmology, and women's healthcare. It offers prescription medicines for cardiovascular and blood diseases that include heart attack, high blood pressure, peripheral arterial occlusive disease, pulmonary hypertension, stroke, and thrombosis; oncological diseases that include breast cancer, liver cancer, non-Hodgkin lymphoma, prostate cancer, and renal cell cancer; ophthalmology that include age-related macular degeneration; hormonal contraception, endometriosis, gynecological diseases, menopausal complaints, and premenstrual dysphoric diso...
Founded in 1851
Key Executives for Bayer Pharma AG
Chairman of Management Board
Chief Financial Officer and Member of Management Board
Head of Specialized Therapeutics Business Area
Head of Latin American Canada Region Operations
Compensation as of Fiscal Year 2014.
Bayer Pharma AG Key Developments
arGEN-X Announces Collaboration with Bayer Pharma AG to Discover and Develop Therapeutic Antibody Candidates
May 28 14
arGEN-X announced the initiation of a collaboration with Bayer Pharma AG, leveraging arGEN-X's SIMPLE Antibody(TM) technology for the discovery and development of therapeutic antibodies. The collaboration centers on a novel approach to addressing complex targets across multiple therapeutic areas that are often intractable by existing antibody platforms. With this collaboration, arGEN-X will apply its SIMPLE Antibody(TM) technology to multiple targets submitted by Bayer. The parties will work together to validate human antibody leads in disease-relevant models, with Bayer being responsible for further preclinical and clinical development and commercialization of therapeutic antibody products. Under the terms of the Agreement, Bayer will pay arGEN-X an upfront technology access fee, research support and technical success-based milestones. Bayer will also pay clinical, regulatory and product sales-based milestones as antibody programs progress through clinical development and registration.
Bayer HealthCare Receives MHLW Approval for Macular Edema Drug
Nov 29 13
Bayer HealthCare has received approval from the Ministry of Health, Labour and Welfare, or MHLW, for EYLEA for the treatment of macular edema secondary to central retinal vein occlusion, or CRVO. EYLEA has also been approved in Europe for the treatment of visual impairment due to macular edema secondary to CRVO as well as in the US and in selected countries in Asia and Latin America for the treatment of macular edema following CRVO.
Bayer Pharma AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013
Sep 25 13
Bayer Pharma AG Presents at BioJapan 2013 World Business Forum, Oct-09-2013 . Venue: Pacifico Yokohama, Yokohama, Japan.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|